These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36126230)

  • 1. A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II.
    Knöchel J; Nilsson C; Carlsson B; Wernevik L; Hofherr A; Gennemark P; Jansson-Löfmark R; Isaksson R; Rydén-Bergsten T; Hamrén B; Rekić D
    CPT Pharmacometrics Syst Pharmacol; 2022 Dec; 11(12):1569-1577. PubMed ID: 36126230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice.
    Graham MJ; Lemonidis KM; Whipple CP; Subramaniam A; Monia BP; Crooke ST; Crooke RM
    J Lipid Res; 2007 Apr; 48(4):763-7. PubMed ID: 17242417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid-Based Therapy Era.
    Gouni-Berthold I; Schwarz J; Berthold HK
    Curr Atheroscler Rep; 2022 Oct; 24(10):779-790. PubMed ID: 35900635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.
    Gupta N; Fisker N; Asselin MC; Lindholm M; Rosenbohm C; Ørum H; Elmén J; Seidah NG; Straarup EM
    PLoS One; 2010 May; 5(5):e10682. PubMed ID: 20498851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial.
    van Poelgeest EP; Hodges MR; Moerland M; Tessier Y; Levin AA; Persson R; Lindholm MW; Dumong Erichsen K; Ørum H; Cohen AF; Burggraaf J
    Br J Clin Pharmacol; 2015 Dec; 80(6):1350-61. PubMed ID: 26261033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program.
    Galluppi GR; Ahamadi M; Bhattacharya S; Budha N; Gheyas F; Li CC; Chen Y; Dosne AG; Kristensen NR; Magee M; Samtani MN; Sinha V; Taskar K; Upreti VV; Yang J; Cook J
    Clin Pharmacol Ther; 2024 Aug; 116(2):282-288. PubMed ID: 38519861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making.
    Madabushi R; Seo P; Zhao L; Tegenge M; Zhu H
    Pharm Res; 2022 Aug; 39(8):1669-1680. PubMed ID: 35552984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model-Informed Drug Development Paradigm.
    Ni L; Khan AZ; Long A; Gao L; Toms N; Gonzalez-Gugel E; Holsmer-Brand S; Lin Y; Abada P; Dickin S; O'Dea D; Wei R; Jen MH; Aggarwal H
    Clin Pharmacol Ther; 2023 Jul; 114(1):77-87. PubMed ID: 37087634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9.
    van Poelgeest EP; Swart RM; Betjes MG; Moerland M; Weening JJ; Tessier Y; Hodges MR; Levin AA; Burggraaf J
    Am J Kidney Dis; 2013 Oct; 62(4):796-800. PubMed ID: 23561896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.
    Rayner CR; Smith PF; Andes D; Andrews K; Derendorf H; Friberg LE; Hanna D; Lepak A; Mills E; Polasek TM; Roberts JA; Schuck V; Shelton MJ; Wesche D; Rowland-Yeo K
    Clin Pharmacol Ther; 2021 Apr; 109(4):867-891. PubMed ID: 33555032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel ASO therapeutic target designed against hyperlipidemia via PCSK9 knockdown.
    Yu X; Song K
    Biomed Pharmacother; 2024 Jan; 170():115960. PubMed ID: 38039754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies.
    Seidah NG
    Curr Pharm Des; 2013; 19(17):3161-72. PubMed ID: 23317404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model-Informed Drug Development in Pediatric Dose Selection.
    Bi Y; Liu J; Li F; Yu J; Bhattaram A; Bewernitz M; Li RJ; Ahn J; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S60-S69. PubMed ID: 34185906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Modern Curriculum for Training Scientists in Model-Informed Drug Development: Progress Report on FDA Grant to Train Regulatory Scientists.
    Barrett JS; Romero K; Rayner C; Gastonguay M; Pillai GC; Tannenbaum S; Kern S; Selich M; Francisco D
    Clin Pharmacol Ther; 2024 Aug; 116(2):289-294. PubMed ID: 39012325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model-informed drug development in pediatric, pregnancy and geriatric drug development: States of the art and future.
    Wu YE; Zheng YY; Li QY; Yao BF; Cao J; Liu HX; Hao GX; van den Anker J; Zheng Y; Zhao W
    Adv Drug Deliv Rev; 2024 Aug; 211():115364. PubMed ID: 38936664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Model-Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling.
    Bi Y; Liu J; Li L; Yu J; Bhattaram A; Bewernitz M; Li RJ; Liu C; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S104-S111. PubMed ID: 31502691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunities and challenges for applying model-informed drug development approaches to gene therapies.
    Belov A; Schultz K; Forshee R; Tegenge MA
    CPT Pharmacometrics Syst Pharmacol; 2021 Apr; 10(4):286-290. PubMed ID: 33608998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S; Serban MC; Banach M
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.